A new study presented at ASCO GU 2025 highlights NSD2 as a promising therapeutic target for treatment-induced neuroendocrine prostate cancer (t-NEPC), an aggressive form of prostate cancer that emerges after standard treatments. Researchers found that inhibiting NSD2, an epigenetic regulator, could slow cancer progression. While still in early stages, this discovery opens new treatment possibilities. They have been using KTX1001, a NSD2 inhibitor currently in clinical evaluation for multiple myeloma.
Thanks to Petabyte for the info!
The human microbiome links to prostate cancer risk and treatment (Review)
Androgen receptor mutations for precision medicine in prostate cancer - Endocrine-Related Cancer, Review Article, Published: 17 Aug 2022